We hope to develop specific targeted inhibitors that affect both immunity and blood vessels to achieve satisfactory anti-tumor effects and prolong the survival of patients in the future, such as evaluating the potential synergistic effects of combined immunotherapy with VEGF inhibitors. The gene discussed is VEGFA; the disease is neoplasm.